Skip to content


Hereditary Cancer in Clinical Practice

Open Access

Identification of a novel disease-associated variant in the BRCA1 3’UTR that introduces a functional miR-103 target site

  • BL Brewster1,
  • F Rossiello2,
  • JD French1,
  • SL Edwards1,
  • EM Wong3,
  • P Whiley4, 6,
  • N Waddell1,
  • BreastCFR,
  • kConFab,
  • X Chen5,
  • B Bove5,
  • AB Spurdle4, 6,
  • P Radice2,
  • AK Godwin5,
  • MC Southey3,
  • MA Brown1 and
  • P Peterlongo2
Contributed equally
Hereditary Cancer in Clinical Practice201210(Suppl 2):A88

Published: 12 April 2012


Breast CancerCancer RiskBreast Cancer RiskBreast Cancer CaseCancer Susceptibility

Mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, represent the majority of the known familial breast cancer risk, yet account for only 20% of the total risk. As BRCA1 is a large gene, genetic screening of high-risk individuals is limited to the coding regions and intron-exon boundaries, which precludes the identification of mutations in non-coding and untranslated (UTR) regions. Although mutations within 3’UTRs have been identified in many genes and are known to influence cancer susceptibility through the disruption or creation of protein and microRNA binding regions, mutation analysis of the BRCA1 3’UTR to date has been very limited. In this study, we screened the BRCA1 3’UTR for potential regulatory mutations. Using a large cohort of 1,585 BRCA-mutation negative, breast cancer cases, we identified seventeen novel BRCA1 3’UTR variants, eight of which were identified in breast cancer cases and absent in a large panel of cancer-free controls. Four of these variants, c.*58C>T, c.*528G>C, c.*718A>G, and c.*1271T>C, significantly reduced 3’UTR associated regulatory activity, as measured by reporter assays using MDA-MB-231 breast cancer cells. In addition, three BRCA1 3’UTR variants, c.*718A>G, c.*800T>C and c.*1340_42TGTdel, were predicted to create new miRNA binding sites. Of these, c.*1340_42TGTdel showed a significant reduction (25%, p=0.0007) in luciferase activity when co-expressed with the predicted targeting miRNA, miR-103 in MCF-7 cells. This is the most comprehensive set of BRCA1 3’UTR variants published to date and highlights the importance of cataloguing 3’UTR variants for functional analyses and cancer risk association.


Authors’ Affiliations

School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
Department of Pathology, The University of Melbourne, Melbourne, Australia
Queensland Institute of Medical Research, Brisbane, Australia
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA
5Fox Chase Cancer Center, Philadelphia, USA


© Brewster et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.